TABLE 1.

Change in body mass index standard deviation score (BMISDS) in different patients characteristics groups

		BMISDS change
	All patients
	No. (%)	Mean	Median	p value a
Overall population	765	0.64	0.61
Age group (years)
Age 2–5.9	464 (60.7)	0.85	0.83
Age 6–9.9	158 (20.7)	0.46	0.48	<.001
Age 10–17.9	143 (18.7)	0.15	0.10
Gender
Male	417 (54.5)	0.62	0.59	.48
Female	348 (45.5)	0.67	0.64
Weight group at diagnosis
Underweight	35 (4.6)	2.27	2.08
Healthy weight	640 (83.7)	0.65	0.65	<.001
Overweight	74 (9.7)	−0.01	0.04
Obese	16 (2.1)	−0.15	−0.13
Risk group
Standard risk treatment	410 (53.6)	0.69	0.64
Intermediate risk treatment	287 (37.5)	0.67	0.63	<.001
High risk treatment	68 (8.9)	−0.09	0.13
Immunophenotype
B‐cell ALL	668 (87.3)	0.67	0.63	.03
T‐cell ALL	97 (12.7)	0.43	0.49
Induction therapy
Prednisolone induction	621 (81.2)	0.68	0.68	.03
Dexamethasone induction	144 (18.8)	0.46	0.47
WBC at diagnosis
WBC <50 × 109/L	602 (78.7)	0.67	0.63
WBC 50–100 × 109/L	73 (9.6)	0.63	0.59	.06
WBC >100 × 109/L	90 (11.8)	0.41	0.51
CNS status at diagnosis
CNS negative ALL	741 (96.9	0.64	0.61	.48
CNS positive ALL	24 (3.1)	0.49	0.54

Abbreviations: ALL, acute lymphoblastic leukemia; CNS, central nervous system; WBC, white blood cell count.

^a Qui‐square test, independent t tests, and one‐way ANOVA are based on mean.